Mr Eiji Katayama > Abe, Ikubo & Katayama > Tokyo, Japan > Lawyer Profile

Abe, Ikubo & Katayama is well-versed in handling disputes, particularly intellectual property infringement litigation, across a broad range of technical fields, such as chemistry and life sciences. Team leader Eiji Katayama specialises in both domestic and cross-border intellectual property and bankruptcy-related disputes. Yasuhiko Ikubo advises on corporate activities and management, while Junichi Kitahara focuses on domestic and international commercial disputes. Other key members are Hirokazu Honda, who provides assistance on intellectual property licenses, joint research, and development; and Kazuyuki Taguchi, who focuses on matters related to financial practices.

The team at Abe, Ikubo & Katayama represents debtors in corporate reorganisations and civil rehabilitation matters, demonstrating its expertise in preparing and executing restructuring plans, as well as completing the reorganisation and rehabilitation processes. The team is led by Kazuyuki Taguchi, who specialises in corporate reorganisations and turnaround business matters, and Hirofumi Kato, who has extensive experience in business rehabilitation, particularly in legal and voluntary liquidation. Eiji Katayama is a key figure in domestic and cross-border matters, focusing on bankruptcy law.

The team at Abe, Ikubo & Katayama has ‘deep knowledge and expertise’ in IP infringement litigation and procurement, benefiting from a combination of experienced litigators and patent lawyers in the chemical, biotech, software, and electronics fields. The team is jointly led by Eiji Katayama, who is well-versed in domestic and cross-border intellectual property-related matters, and Hiroshi Kobayashi, who is experienced in infringement, opinion, licensing, and opposition patent-related matters. Junichi Kitahara and Makoto Hattori focus on patent litigation and trade secret litigations, respectively, representing both domestic and international clients. Mami Hino is a name to note in relation to pharma patent protection.